MARIETTA, Ga.--(BUSINESS WIRE)--Solvay Pharmaceuticals, Inc. and Jazz Pharmaceuticals, Inc., announced today a product license agreement under which Jazz Pharmaceuticals will have the right to market LUVOX® (fluvoxamine maleate) Tablets and fluvoxamine maleate extended-release capsules, upon approval by the Food and Drug Administration (FDA), in the United States. Solvay Pharmaceuticals will retain the right to market both products in other territories around the world.
